阿帕替尼治疗晚期化疗耐药胃癌的临床体会

摘要

Objective:To investigate the efficacy and clinical features of Apatinib in the treatment of chemotherapy resistant advanced gastric cancer.Methods:We reported two cases of advanced gastric cancer treated with Apatinib. Clinical efficacy,toxicity and imaging changes were observed.Results:After treatment,lesions of the two cases were liquefied,and CT value decreased.The side effects of hand foot syndrome and diarrhea occurred during the treatment period.The overall survival of the first patient was prolonged for 7 months.The progression free survival of the second patient was 6 months and he was in continuous treatment.Conclusion:Apatinib can obtain good clinical effect in treatment of chemotherapy resistant advanced gastric cancer.There would have association between the efficacy of Ap-atinib and adverse reactions of hand foot syndrome and diarrhea.The efficacy evaluation criteria of molecular targeted drug can not only be limited to RECIST,and need to be improved further.%目的：探讨阿帕替尼治疗晚期化疗耐药的胃癌疗效及临床特点。方法：报道阿帕替尼治疗晚期化疗耐药的2例胃癌的临床疗效、不良反应及影像学变化并结合文献讨论。结果：第一例患者服药后的总生存期又延长了7个月。第二例患者的无进展生存期达6个月，仍在继续服药中。两例患者治疗后病灶均出现液化，影像学上表现为 CT 值下降。治疗期间均出现手足综合征和腹泻的不良反应。结论：阿帕替尼治疗晚期化疗耐药的胃癌可以获得较好的疗效。阿帕替尼的疗效与手足综合征和腹泻的不良反应等可能有相关性。分子靶向药物的疗效评价标准不能仅局限于 RECIST，需要进一步完善。